NASD · Healthcare · Biotechnology · Netherlands
NewAmsterdam Pharma Company NV is a mid cap company (market value between $2 billion and $10 billion) in the Biotechnology industry.
NewAmsterdam Pharma Company is a biopharmaceutical company developing obicetrapib, an oral cholesteryl ester transfer protein inhibitor for lowering LDL-C in patients with cardiometabolic diseases. The company is investigating obicetrapib as both a monotherapy and in combination with ezetimibe through clinical trials, and has partnered with Menarini for commercialization in Europe.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the NewAmsterdam Pharma Company NV stock.
Overvalued: intrinsic value $4.93 per share, market price $20.06, margin of safety -306.5% (as of 2026-10-30).
Its liquidation floor, current assets minus every liability, values the shares at $4.93; the price of $20.06 is 307% above that value.
9 more funds hold it; the full list is part of the paid plan.
81 more in this industry show a wider margin of safety.
NAMS is overvalued (as of the 2026-10-30 close). Its liquidation floor, current assets minus every liability, values the shares at $4.93; the price of $20.06 is 307% above that value.
$4.93 per share (as of the 2026-10-30 close), against a market price of $20.06. That is a margin of safety of -306.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.